<DOC>
	<DOCNO>NCT02313285</DOCNO>
	<brief_summary>Primary Objective : To assess long-term safety GZ402668 patient multiple sclerosis ( MS ) receive prior treatment TDU13475 TDU14981 study . Secondary Objectives : To assess pharmacokinetics GZ402668 patient MS. To assess pharmacodynamics GZ402668 patient MS. To assess immunogenicity GZ402668 patient MS .</brief_summary>
	<brief_title>A Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies GZ402668</brief_title>
	<detailed_description>The total study duration patient approximately 47 month . There administration GZ402668 LTS14120 study . Patients already receive investigational medicinal product ( GZ402668 placebo ) TDU13475 TDU14981 follow 47 month LTS14120 . Note : Patients TDU14981 study ( sanofi-sponsored ) participate LTS14120 study . In order keep consistent among study relate document , title LTS14120 study amend .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Inclusion criterion : Received investigational medicinal product ( GZ402668 placebo ) TDU13475 TDU14981 The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>